Cilostazol Following Peripheral Endovascular Procedures

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the safety and effectiveness of dual anti-platelet therapy with cilostazol 100 mg twice daily and aspirin 100 mg daily versus monotherapy with aspirin 100 mg daily in patients undergoing peripheral angioplasty or stenting or both for the management of peripheral arterial disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Attikon Hospital
• Collaborator: University Hospital of Patras
• Treatments: Aspirin; Cilostazol

Criteria

Inclusion Criteria:

• Scheduled infrainguinal (femoropopliteal or infrapopliteal or both) angioplasty and/or stenting.

• Surgical or endovascular treatment of Inflow iliac artery significant stenosis if deemed necessary.

• Symptomatic severe intermittent claudication (Rutherford-Becker 3) or critical limb ischemia (Rutherford-Becker 4-6).

• Informed consent signed

Exclusion Criteria:

• Any contraindication to aspirin or cilostazol intake

• No pedal arch outflow

• Sole iliac artery treatment

• Standard contraindications to angioplasty

• Acute or sub-acute limb ischemia